In a pivotal shift for China’s pharmaceutical landscape, the latest round of national volume-based procurement (VBP) in Wuhan has finally breached the last stronghold of retail drugstores: the over-the-counter (OTC) market. This fourth batch of centralized buying for Traditional Chinese Medicine (TCM) signifies a tightening grip by the state on drug prices that were once the primary profit engine for private retailers. For the first time, household staples like digestive aids and cold remedies are subject to the same aggressive discounting as life-saving hospital drugs.
For years, major brands such as CR Sanjiu and CR Jiangzhong enjoyed a level of price immunity because their products were primarily sold in retail pharmacies rather than public hospitals. The inclusion of 89 drug types in this round, including blockbuster items with annual sales exceeding 100 million yuan, marks the end of that sanctuary. With expected price drops averaging 40% to 50%, and some exceeding 60%, the retail sector’s traditional business model is facing an existential crisis.
Pharmacy chains are particularly vulnerable to this policy shift. Data indicates that TCM accounts for roughly 40% of total sales for major chains, providing the high margins necessary to sustain aggressive physical expansion. Historically, these retailers thrived on price fragmentation, where the same herbal extract could be sold at vastly different price points depending on the brand and packaging. By standardizing procurement, the state is stripping away the brand premium that players spent decades building through expensive advertising.
The financial strain is already visible in the balance sheets of industry leaders. Revenue and profit growth have stalled for giants like Yixintang and Laobaixing as they grapple with the "Triple Entry" policy, which forces VBP-priced drugs into neighborhood stores. As low-cost versions of popular digestive tablets and cough syrups flood the market, the price wars previously confined to the hospital sector are now being fought in every local pharmacy aisle.
To survive, the industry is attempting a painful transition from pure retail to comprehensive health services. Firms are now experimenting with "Health Stations" that offer diagnostic consultations and chronic disease management. The hope is that professional service fees and patient loyalty can eventually replace the disappearing margins of herbal pills, but the success of this pivot remains unproven in a market where consumers are accustomed to free advice and cheap medicine.